SOX9 and neoplasm: CRISPR/Cas9 offers permanent genomic editing of SOX loci, bypassing delivery instability by enabling knockout or base editing in preclinical patient-derived tumor xenograft models (128–130), where SOX9 ablation halts metastasis more durably than siRNA.